Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies
- 27 May 2014
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 54 (11) , 1230-1238
Abstract
Brodalumab, a human monoclonal IgG2‐antibody, acts as a potent antagonist at the interleukin‐17 receptor A, which is important in the pathogenesis of psoriasis. To characterize the pharmacokinetics of brodalumab and assess the effects of covariates, brodalumab concentrations from Phase 1a and Phase 2 clinical studies in healthy adults and subjects with psoriasis were used to construct a population PK model. The final two‐compartment model with parallel linear and non‐linear elimination pathways fit the data well. The population typical values for PK parameters CL, V, and Vmax were 0.223 L/day, 4.62 L, and 5.40 mg/day with between‐subject‐variability of 69.2, 69.6, and 25.9%CV, respectively. Body weight (BW) was an important covariate on CL (and Q), V (and V2) and Vmax, with estimated effect exponents of 0.598, 0.849, and 1.12, respectively. Based on simulations from the final model, for doses between 140 and 210 mg, AUC was predicted to be greater than two fold higher in subjects weighing less than 75 kg compared to reference subjects. Age and diagnosis had smaller influence on exposure and was not clinically significant. These data suggest that BW is an important covariate explaining some of the variability in population PK observed in human clinical trials with brodalumab.Keywords
This publication has 23 references indexed in Scilit:
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and PrevalenceJournal of Investigative Dermatology, 2013
- Facilitating pharmacometric workflow with the metrumrg package for RComputer Methods and Programs in Biomedicine, 2013
- Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled TrialJournal of Investigative Dermatology, 2012
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for PsoriasisNew England Journal of Medicine, 2012
- Recent advances in the IL-17 cytokine familyCurrent Opinion in Immunology, 2011
- Population Pharmacokinetic Analysis of Istradefylline in Healthy Subjects and in Patients With Parkinson's DiseaseThe Journal of Clinical Pharmacology, 2011
- Population Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010
- Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancerBritish Journal of Cancer, 2010
- Population pharmacokinetic analysis of varenicline in adult smokersBritish Journal of Clinical Pharmacology, 2009
- Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skinBritish Journal of Dermatology, 2009